Dr. Rhonda Voskuhl Featured on NBC’s Today Show Highlighting Menopause and Brain Health | CleopatraRX

Dr. Rhonda Voskuhl Featured on NBC’s Today Show Highlighting Menopause and Brain HealthVon Greer2025-05-21T21:33:50+00:00

**Dr. Rhonda Voskuhl Featured on NBC’s Today Show Highlighting Menopause and Brain Health**

December 26, 2024

Dr. Rhonda Voskuhl, Professor of Neurology at the University of California, Los Angeles (UCLA), and a globally recognized expert in women’s brain health, was recently featured on NBC’s Today Show alongside Maria Shriver. The segment, aired on December 26, 2024, focused on the critical link between menopause and cognitive health, shedding light on innovative treatments to empower women during this transformative life stage.

Dr. Voskuhl, the faculty neurologist for the UCLA Comprehensive Menopause Care Program and Director of the UCLA Multiple Sclerosis Program, discussed her groundbreaking research on the neuroprotective effects of estrogen, particularly estriol, during menopause. She highlighted how cognitive challenges, such as memory lapses and difficulty focusing, affect 70% of menopausal women and shared insights into her patented treatment, PearlPAK™, developed by CleopatraRX. This novel hormone therapy, based on over 25 years of NIH-funded research, aims to address cognitive decline in perimenopause and early menopause with a safer profile than traditional hormone therapies. “Our goal is to empower women to take control of their brain health and thrive during menopause,” Dr. Voskuhl stated on the show.

Hosted by Maria Shriver, the segment emphasized the need for open conversations about menopause and the importance of scientific advancements in women’s health. Dr. Voskuhl’s appearance underscored her leadership in translating clinical observations into transformative treatments, a “bedside to bench to bedside” approach that has earned her international acclaim, including the Rachel Horne Prize for Women’s Research in MS and the John Dystel Prize from the American Academy of Neurology.

Watch the full segment here:

https://www.today.com/video/how-a-new-menopause-treatment-focuses-on-cognitive-health-227920453880

Back to Press Room

© Copyright 2025 CleopatraRX™. All Rights Reserved. View our Privacy Policy. and Terms and Conditions.

*PearlPAK™️ dose system is not intended to treat neurological diseases including dementia and Alzheimer’s Disease. It is specifically designed to target cognitive difficulties in perimenopause and early menopausal women only. If you are concerned about neurological disease or have a family history of neurological disease, contact your physician.

CleopatraRX™ and PearlPAK™ are trademarks of CleopatraRX Development, LLC. CleopatraRX™ is a service mark and is used throughout this website to represent the services offered by CleopatraRX Development, LLC. PearlPAK™ is a dosage product for use as a drug/routine system and/or treatment.

The PearlPAK™️ drug/routine system is protected by U.S. Patent No. 10,369,158 – PHARMACEUTICAL PACKAGING FOR ESTRIOL THERAPY – which relates to novel packaged pharmaceutical products for the treatment of neurodegenerative diseases, such as multiple sclerosis, and methods of using these products.

Estriol Therapy U.S. Patent No. 9,962,395 – COMPOSITIONS AND METHODS FOR MAINTAINING COGNITIVE FUNCTION – Provides methods for reducing the progression of cognitive decline in a post-menopausal woman using a continuous regimen of estrogen in combination with periodic administration of a progestogen.

*PearlPAK™ dose system is not intended to treat neurological diseases including dementia and Alzheimer’s Disease. It is specifically designed to target cognitive difficulties in perimenopause and early menopausal women only. If you are concerned about neurological disease or have a family history of neurological disease, contact your physician.

CleopatraRX™ and PearlPAK™ are trademarks of CleopatraRX Development, LLC. CleopatraRX™ is a service mark and used throughout this website to represent the services offered by CleopatraRX Development, LLC. PearlPAK™ is a dosage product is for use as a drug/routine system and/or treatment.

The PearlPAK™ drug/routine system is protected by U.S. Patent No. 10,369,158 – PHARMACEUTICAL PACKAGING FOR ESTRIOL THERAPY – which relates to novel packaged pharmaceutical products for the treatment of neurodegenerative diseases, such as multiple sclerosis, and methods of using these products.

Estriol Therapy U.S. Patent No. 9,962,395 – COMPOSITIONS AND METHODS FOR MAINTAINING COGNITIVE FUNCTION – Provides methods for reducing the progression of cognitive decline in a post – menopausal woman using a continuous regimen of estrogen in combination with periodic administration of a progestogen.